arrow
L

Laure Vincent

University Hospital of Montpellier
H指数:27
被引数:3,135

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Longitudinal assessments of MRD in high-risk newly diagnosed transplant-ineligible multiple myeloma in the BENEFIT study (IFM2020-05)

BENEFIT研究(IFM2020-05)中高危初诊非移植候选多发性骨髓瘤的MRD纵向评估

2026-10-050
OAAI
The cumulative effect of cytogenetic abnormalities on the outcomes of myeloma patients with del(17p) undergoing AHSCT in EBMT centres between 2016 and 2022

2016年至2022年间EBMT中心中,17p缺失的骨髓瘤患者在接受AHSCT时,细胞遗传学异常的累积效应对其预后的影响

2026-09-050
OAAI
CD200 is a potent new growth factor in Multiple Myeloma dependent on IGF1 receptor signaling

CD200是一种依赖于IGF1受体信号传导的多发性骨髓瘤新型强效生长因子

2026-08-280
OAAI
Clinical outcomes of newly diagnosed myeloma patients with SLIM criteria : a subgroup analysis of the CASSIOPEIA study

新诊断多发性骨髓瘤患者SLIM标准下的临床结局:CASSIOPEIA研究中的亚组分析

Leukemia
IF13.4
2026-08-130
PRE
Response profile and long-term outcomes in Cyclin D1-overexpressing multiple myeloma: insights from the CASSIOPEIA trial

Cyclin D1过表达多发性骨髓瘤的反应特征和长期结局:来自CASSIOPEIA试验的见解

2026-07-030
OAAI
Real-world evidence of immunotherapy sequencing in multiple myeloma: Durable responses with BCMA-targeting bispecific antibodies following prior GPRC5D-targeting therapy.

多发性骨髓瘤免疫疗法序贯治疗的现实世界证据:GPRC5D靶向疗法后使用BCMA靶向双特异性抗体可获持久应答

2026-06-140
PRE
A dexamethasone-free daratumumab–ixazomib regimen in frail elderly patients with relapsed or refractory multiple myeloma: Results of the IFM 2018-02 phase II study

无地塞米松的达拉木单抗–伊沙佐米方案在老年复发或难治性多发性骨髓瘤患者中的应用:IFM 2018-02 II期研究的结果

2026-05-070
PRE
Assessing the benefit of incorporating ananti-CD38 monoclonal antibody into second-or third-line systemic treatment for patients with relapsed/refractory multiple myeloma: results from the French real-world EMMY study

评估将抗CD38单克隆抗体纳入复发/难治性多发性骨髓瘤患者二线或三线系统性治疗中的获益:法国真实世界EMMY研究的结果

2026-02-010
OAAI
Comparative Efficacy of Talquetamab vs. Real-World Physician’s Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent

三药类暴露的复发/难治性多发性骨髓瘤中塔奎他单抗与真实世界医生选择治疗的比较疗效:MonumenTAL-1与LocoMMotion/MoMMent的更新分析

2025-11-280
OAAI
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience

35年专注于高剂量疗法和自体干细胞移植的学术研究:法国骨髓瘤研究组(IFM)的经验

2025-10-240
OA
Debulking strategy prior to anti-BCMA/CD3 bispecific antibodies in extramedullary and/or high tumor burden RRMM: a retrospective cohort study

减瘤策略在髓外和/或高肿瘤负荷RRMM患者接受抗BCMA/CD3双特异性抗体治疗前:一项回顾性队列研究

2025-10-210
OA
Dexamethasone added to induction and post-remission therapy in older patients with newly diagnosed acute myeloid leukemia: a multicenter, phase II trial (DEXAML-02)

地塞米松添加到新诊断急性髓系白血病老年患者的诱导和缓解后治疗中:一项多中心、II期试验(DEXAML-02)

2025-10-011
OAAI
Poor Outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study

从ide-cel早期复发后使用靶向BCMA的双特异性抗体治疗效果不佳:一项法国真实世界研究

2025-09-200
OAAI
Real-world utilization of carfilzomib (once or twice weekly) initiated in patients after a first relapse between 2017-2022 in France: an analysis from a large-scale Epidemiology of Multiple MYeloma (EmmY) cohort

2017-2022年间法国在首次复发后的多发性骨髓瘤患者中开始使用卡非佐米(每周一次或两次)的实时应用:来自大规模多发性骨髓瘤流行病学(EmmY)队列的分析

2025-08-070
OAAI
The Impact of Anti-CD38 Monoclonal Antibodies in Frontline Therapy for Patients With Newly Diagnosed Multiple Myeloma: Real-Life Results From the EMMY Study

抗CD38单克隆抗体在初诊多发性骨髓瘤患者一线治疗中的影响:来自EMMY研究的真实世界结果

2025-07-240
PRE
CD200 immune checkpoint expression is associated with inferior outcome in multiple myeloma patients treated with anti-CD38 monoclonal antibodies

CD200免疫检查点表达与接受抗CD38单克隆抗体治疗的骨髓瘤患者不良预后相关

2025-07-200
OA
Retreatment With Anti-CD38-Based Combinations in Multiple Myeloma in Real-Life: Results From the Emmy Cohort Study

基于抗CD38的联合方案在多发性骨髓瘤中的真实世界再治疗:来自Emmy队列研究的结果

2025-05-210
OAAI
Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results

达拉妥单抗-硼替佐米-沙利度胺-地塞米松用于新诊断的骨髓瘤:CASSIOPEIA微小残留病结果

Blood
IF23.1
2025-03-260
OA